0R44 Stock Overview
Develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the America, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
C-Rad AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr42.50 |
| 52 Week High | kr49.00 |
| 52 Week Low | kr25.85 |
| Beta | 0.95 |
| 11 Month Change | 1.43% |
| 3 Month Change | 0.71% |
| 1 Year Change | 55.29% |
| 33 Year Change | -25.44% |
| 5 Year Change | n/a |
| Change since IPO | 26.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0R44 | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0.2% | 0.06% | 1.7% |
| 1Y | 55.3% | -11.1% | 8.9% |
Return vs Industry: 0R44 exceeded the UK Medical Equipment industry which returned -11.1% over the past year.
Return vs Market: 0R44 exceeded the UK Market which returned 8.9% over the past year.
Price Volatility
| 0R44 volatility | |
|---|---|
| 0R44 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0R44 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0R44's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 89 | Cecilia De Leeuw | www.c-rad.com |
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the America, and the Asia Pacific. Its products include Sentinel 4DCT, a laser-based optical surface scanning system; Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy, that supports proton therapy from simulation and treatment; and Catalyst+ HD Ring Gantry solution for patient positioning, real-time motion monitoring, and respiratory gating. The company provides Catalyst, a 4D surface guided radiation therapy (SGRT) solution; Catalyst HD, a SGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst PT, a tracking solution for particle therapy; and visual coaching solutions used for prospective and retrospective radiotherapy.
C-Rad AB (publ) Fundamentals Summary
| 0R44 fundamental statistics | |
|---|---|
| Market cap | kr1.43b |
| Earnings (TTM) | kr48.33m |
| Revenue (TTM) | kr458.22m |
29.6x
P/E Ratio3.1x
P/S RatioIs 0R44 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0R44 income statement (TTM) | |
|---|---|
| Revenue | kr458.22m |
| Cost of Revenue | kr151.79m |
| Gross Profit | kr306.43m |
| Other Expenses | kr258.10m |
| Earnings | kr48.33m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 18, 2024
| Earnings per share (EPS) | 1.44 |
| Gross Margin | 66.87% |
| Net Profit Margin | 10.55% |
| Debt/Equity Ratio | 0% |
How did 0R44 perform over the long term?
See historical performance and comparison